BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30151740)

  • 1. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
    Watanabe N; Takaku T; Takeda K; Shirane S; Toyota T; Koike M; Noguchi M; Hirano T; Fujiwara H; Komatsu N
    Int J Hematol; 2018 Dec; 108(6):588-597. PubMed ID: 30151740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large granular lymphocytosis during dasatinib therapy.
    Qiu ZY; Xu W; Li JY
    Cancer Biol Ther; 2014 Mar; 15(3):247-55. PubMed ID: 24352048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
    Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
    Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
    Kim DH; Kamel-Reid S; Chang H; Sutherland R; Jung CW; Kim HJ; Lee JJ; Lipton JH
    Haematologica; 2009 Jan; 94(1):135-9. PubMed ID: 19066329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
    Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
    Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
    Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
    Uchiyama T; Sato N; Narita M; Yamahira A; Iwabuchi M; Furukawa T; Sone H; Takahashi M
    Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
    Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
    Cancer Sci; 2020 Aug; 111(8):2923-2934. PubMed ID: 32614159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib.
    Shimura Y; Horiike S; Tsutsumi Y; Hatsuse M; Okano A; Fuchida S; Kobayashi T; Matsumoto Y; Kuroda J; Kawata-Iida E; Uchiyama H; Uoshima N; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    Int J Hematol; 2015 Oct; 102(4):426-33. PubMed ID: 26267232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.
    Yao D; Xu L; Liu L; Zeng X; Zhong J; Lai J; Zheng R; Jin Z; Chen S; Zha X; Huang X; Lu Y
    Biomed Res Int; 2020; 2020():9531549. PubMed ID: 33102599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nilotinib treatment induced large granular lymphocyte expansion and maintenance of longitudinal remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Hagihara M; Hua J; Inoue M; Uchida T; Ide S; Ohara S; Takaku T
    Int J Hematol; 2020 May; 111(5):719-723. PubMed ID: 31894532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Sep; 90(9):819-24. PubMed ID: 26103598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
    El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
    J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
    Tanaka H; Nakashima S; Usuda M
    Int J Hematol; 2012 Sep; 96(3):308-19. PubMed ID: 22767140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes.
    Iriyama N; Hatta Y; Takei M
    Cancer Med; 2016 Nov; 5(11):3223-3234. PubMed ID: 27726309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
    Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
    Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TCRalphabeta+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder.
    Lima M; Almeida J; Dos Anjos Teixeira M; Alguero Md Mdel C; Santos AH; Balanzategui A; Queirós ML; Bárcena P; Izarra A; Fonseca S; Bueno C; Justiça B; Gonzalez M; San Miguel JF; Orfao A
    Am J Pathol; 2003 Aug; 163(2):763-71. PubMed ID: 12875995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.